Intelliject and SNY received tentative FDA approval for their 505(b)(2) application for e-cue, a novel epinephrine delivery device in July 2011. This agreement will allow this competing product to enter the market in November 2012.
Antares $AIS and Teva are developing a generic epi-pen and have filed an ANDA. Pfizer (originally King Pharma $KG) filed patent infringement lawsuits (based on more recently issued patents around a "next-generation" autoinjector) against Teva/AIS and Intelliject/SNY. The consolidated trial was scheduled to begin this week, but now will only involve TEVA/AIS vs PFE.
What does the settlement mean for AIS? Keep in mind that TEVA and AIS are seeking approval for a generic (ANDA pathway) device that closely resembles the branded product, while the Intelliject auto-injector is vastly different (link). Therefore the degree to which the two products potentially infringe on the branded epi-pen is dramatically different.
Certainly a settlement between PFE and TEVA/AIS is still possible, but one shouldn't read much into the terms (especially negotiated launch date) in the settlement announced today as an example. For now, the trial is underway and we will await further developments. Launch of the epi-pen or another Teva-partnered injector product is a crucial milestone on the path to profitability for Antares Pharma that has been repeatedly delayed.